Histone Deacetylase Inhibitors Increase p27(Kip1) by Affecting Its Ubiquitin-Dependent Degradation through Skp2 Downregulation

Histone deacetylase inhibitors (HDACIs) represent an intriguing class of pharmacologically active compounds. Currently, some HDACIs are FDA approved for cancer therapy and many others are in clinical trials, showing important clinical activities at well tolerated doses. HDACIs also interfere with th...

Descripción completa

Detalles Bibliográficos
Autores principales: Borriello, Adriana, Naviglio, Silvio, Bencivenga, Debora, Caldarelli, Ilaria, Tramontano, Annunziata, Speranza, Maria Carmela, Stampone, Emanuela, Sapio, Luigi, Negri, Aide, Oliva, Adriana, Sinisi, Antonio Agostino, Spina, Annamaria, Della Ragione, Fulvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670678/
https://www.ncbi.nlm.nih.gov/pubmed/26682002
http://dx.doi.org/10.1155/2016/2481865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670678/
https://www.ncbi.nlm.nih.gov/pubmed/26682002
http://dx.doi.org/10.1155/2016/2481865

Ejemplares similares